Sentences with phrase «survival for patients»

For most types of lymphoma, the median survival for patients receiving no treatment is 30 days.

Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database.

There was a telling quote from Michael Davies, MD, of the center's Melanoma Medical Oncology Department: «The average survival for patients with stage 4 metastatic melanoma is 6 to 10 months, and this hasn't changed for 30 years.»

Now, a new study suggests the same inexpensive pill might extend survival for patients battling cancers of the gastrointestinal tract — including tumors of the colon and esophagus.

Antiangiogenesis Therapy Improves Overall Survival for Patients with Advanced Cervical Carcinoma Read more

In particular, Dr. Azad's laboratory and clinical trials explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs.

Home - visiting programs and multidisciplinary heart failure clinic interventions can reduce hospital readmission and improve survival for patients with heart failure, according to research from RTI International and the University of North Carolina at Chapel Hill.

Compared with a historical control trial, AIDA 0493, which used a significantly higher anthracycline dose and did not include ATO consolidation, the event - free survival for patients with standard - risk disease in this trial was noninferior.

Five - year progression - free survival for patients with high let - 7 and low HGMA2 was nearly 40 percent.

«Overall survival for patients with HIV infection after transplant is comparable to that seen in people who were not HIV - infected,» said lead author Joseph Alvarnas, MD, associate clinical professor in the department of hematology and director of value - based analytics at the City of Hope National Medical Center in Duarte, CA.

«Newly developed nomograms provide accurate predictions for patients with oropharyngeal cancer: Nomograms provide accurate prediction of overall survival and progression - free survival for patients with oropharyngeal cancer.»

As in - hospital cardiac arrest affects approximately 200,000 individuals annually in the United States, there is a need to understand whether therapeutic hypothermia is associated with improved survival for these patients.

The one - year survival rate for patients on dialysis was 50 percent in 1995 and 95 percent in 2013; survival for patients on a ventilator was 49 percent in 1994 and 94 percent in 2013.

«Bevacizumab (Avastin) fails to improve survival for patients newly diagnosed with glioblastoma.»

Dr Iain Foulkes, executive director for research funding at Cancer Research UK, said: «We're investing in pioneering ways to improve survival for patients.

«There is evidence that surgery could lead to improved survival for these patients.»

«New biomarker allows better prediction of survival for patients with colorectal metastases.»

It's the only drug ever to lengthen survival for those patients.

«Immunotherapy, pembrolizumab, is active against mucosal melanoma tumors: And prolongs survival for patients with bladder cancer.»

«Also, circadian disruption in cancer patients aggravates the prognosis of the disease and the chance of survival for these patients diminishes,» Elisabet Ortiz Tudela, a researcher at the University of Murcia, said.

Median overall survival for patients on selumetinib was 11.8 months, compared with 9.1 months for those on chemotherapy, but the difference was not statistically significant.

The study was a randomized phase II trial testing whether the addition of local treatment, in the form of consolidative radiation therapy, to the standard treatment of systemic therapy improved progression - free survival for patients with limited metastatic NSCLC.

Though uveal melanoma is rare — there are only 2,500 cases diagnosed in the United States each year — about half of patients will develop metastatic disease, and survival for patients with advanced disease has held steady at nine months to a year for decades.

The median survival for patients is 15 months, with less than five per cent of patients surviving beyond five years.

The researchers found that high expression of the tumor - suppressor ZMYND11 is associated with longer survival for patients with triple - negative breast cancer.

«Lenalidomide maintenance therapy improves overall survival for patients with multiple myeloma.»

«Overall, survival for patients with recurrent rhabdomyosarcoma is just 17 percent, and until now nothing was known about how tumors evolve in response to therapy,» said corresponding author Michael Dyer, Ph.D., a member of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute Investigator.

Progression - free survival for patients in both the low - and high - dose groups was identical, about 8.6 months.

A team of Swedish researchers finds that early cardiopulmonary resuscitation more than doubles the chance of survival for patients suffering out - of - hospital cardiac arrest.

There is at least one approved device and scores of experimental treatments being tested that could improve the odds of longer - term survival for patients with the type of extremely aggressive brain cancer afflicting U.S. Sen. John McCain.

This could mean a better chance of survival for these patients».

«This delay in treatment can cause the cancer to advance and reduce the odds of survival for the patient.»

Prophylactic surgery to remove a contralateral breast during breast cancer surgery (known as contralateral prophylactic mastectomy) reduces the risk of breast cancer in that breast (2,4,5,13), although it is not yet known whether this risk reduction translates into longer survival for the patient (13).

Not exact matches

Amgen Executive Vice President of Research and Development Sean Harper said the study was designed to explore Kyprolis dosing regimens, noting that the the trial did not meet its goal in improving progression - free survival versus Velcade in patients who had not yet been treated for the disease.

Approved by the FDA in 2011 for metastatic melanoma, Yervoy was the first drug to offer a survival benefit to patients with that disease.

The survival rates for these patients are extremely low, topping out at about 10 %, because care doesn't arrive nearly fast enough.

Related Articles: Merck's Keytruda held back by docs who don't want to wait for diagnostics Bristol's Opdivo - Yervoy combo ups response rates in first - line lung cancer patients Roche's Tecentriq bursts onto immuno - oncology scene, with Merck and BMS in its sights Bristol - Myers» new Opdivo ad touts biomarker advantage over Merck's Keytruda Merck's Keytruda lines up its survival data for stepped - up battle with BMS» Opdivo

New York, Wall Street Journal — Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new - generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.

The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.

This surgeon was one of the best in this field and had even successfully tried a treatment on this exact cancer for other patients that tripled the five - year - survival odds — from 5 percent to 15 percent — albeit with a poor quality of life.

Sara Hiom, Cancer Research UK's director of health information, said: «Survival rates for breast cancer have been improving for more than 20 years - eight out of ten patients now survive more than five years.

The state's Commissioner for Health, Dr. Olurotimi Ojo, who made the announcement on Monday at a stakeholders» meeting on Lassa fever in Ado Ekiti, said the patient has been isolated as doctors are battling to ensure her survival.

Various treatment regimens have failed to improve PDAC patient survival, driving the critical need for finding druggable targets essential for tumor maintenance.

Importantly, analyses of overall survival rates and melanoma - specific survival rates for pregnancy - associated melanomas versus non-pregnancy-associated melanomas in stages 0 to III melanoma showed no differences (due to the lack of patients with stage IV melanoma, those patients were excluded from the analyses).

The findings could have big implications for the treatment of P. aeruginosa biofilm infections, as an understanding of the pathways that contribute to P. aeruginosa survival and virulence could inform treatment approaches for patients.

This recommendation is based on a separate study published in The Lancet, for which Garon was the senior author, showing longer survival than chemotherapy among patients with any positive staining for PD - L1.

Results of the trial, reported in the May 31 issue of the New England Journal of Medicine and presented at the American Society for Clinical Oncology 2015 annual meeting, also showed that after a year, the nivolumab group had nearly double the survival rate (42 percent) of the chemotherapy patients (24 percent).

«Patients who respond to immunotherapy tend to continue their responses for long durations, and these lengthier responses are cut off in calculations of median overall survival,» she says.

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

There is currently no effective treatment for this stage of leukemia, and patients have only a 5 percent chance of survival over five years.